Tomasz Grabowski

Company: JJP Biologics

Job title: Head of Preclinical Development

Seminars:

Modeling Melanoma Resistance: Using Tumour Models to Validate JJP-1008 mAb Targeting CD160 & CD272 12:45 pm

Identifying CD160 and CD272 as key contributors to melanoma resistance in preclinical models, highlighting their clinical relevance in tumour immune evasion Demonstrating JJP-1008 as the first selective CD270 inhibitory signal-blocking IgG4 mAb, showing promising potential in overcoming melanoma resistance in model systems Showing through preclinical studies that JJP-1008 induces the shedding of LIGHT (CD258), offering…Read more

day: Conference Day One